Message #9 From:
Stock News Bot Date: September 26, 2006 05:30:00 AM
IOPM News IntraOp Medical Corporation Delivers Mobetron to Leading Cancer Center in The Netherlands
SUNNYVALE, Calif.--(BUSINESS WIRE)--IntraOp Medical Corporation (OTCBB: IOPM), a provider of
innovative technology solutions for the treatment and eradication of
cancer, today announced that it has delivered a Mobetron®
to the MCH Westeinde Hospital in The Hague. MCH is one of the major
cancer centers in The Netherlands and treats more than 2000 patients
each year. The Mobetron system is designed exclusively for
intraoperative electron radiation therapy (IOERT), which is the direct
application of radiation to a tumor while a patient is undergoing cancer
surgery. This will be only the second IOERT system in The Netherlands.
Medical Center Haaglanden (MCH) is the second Dutch Hospital to take
delivery of a Mobetron. Dr. Joost van der Sijp, the oncology surgeon,
and Professor Doctor Henk Struikmans, the radiation oncologist, are
responsible for developing the IOERT program at MCH. They state: “We
are looking forward to getting our Mobetron in clinical operation. In
addition to using IOERT for rectal cancer, we plan to use it for breast
conserving therapy in early stage breast cancer patients.”
“It is a privilege to be working with an
institution like MCH,” said Donald A. Goer,
President and Chief Executive Officer of IntraOp. “MCH
has a strong commitment to integrate IOERT into their cancer program. It
is centers like MCH that make a real difference in the lives of the
patients they treat.”
With Mobetron, radiation and surgical oncologists can pinpoint the exact
area that requires radiation and immediately deliver high doses directly
to the affected tissue during cancer surgery. Hospitals can wheel
Mobetron between existing operating rooms without the costly renovations
required to accommodate traditional radiation therapy devices. Key
patient benefits of this early and powerful start to radiation therapy
include: increased survival rates, better local tumor control, shorter
treatment cycles, and fewer side effects.
About Medical Center Haaglanden
Medical Center Haaglanden in The Hague and Leidschendam is one of
eighteen comprehensive cancer centers in the Netherlands that provide
cancer treatment to the 16 million people in the Netherlands. It will be
the second center that offers intraoperative electron beam treatment for
cancer patients in the Netherlands. Of note, the Mobetron was originally
going to be purchased with private funds from an investment group, but
the Health Care Institutions subsequently agreed to financially support
this initiative.
About IntraOp
IntraOp Medical Corporation provides innovative technology solutions for
the treatment and eradication of cancer. Founded in 1993, IntraOp is
committed to providing the tools doctors need to administer radiation
therapy safely and effectively – for all
cancer patients. The company’s flagship
product, Mobetron, is the first fully portable, self-shielding
intraoperative electron radiation therapy device designed for use in any
operating room. Key Mobetron benefits include: increased survival rates,
better local tumor control, shorter treatment cycles, and fewer side
effects. Leading hospitals, from university research centers to
specialized cancer clinics in North America, Europe and Asia, use
Mobetron as a vital part of their comprehensive cancer program.
For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com
Forward-Looking Statements
This press release may contain "forward-looking statements" within
the meaning of Section 27A of the 1933 Securities Act and Section 21E of
the 1934 Securities Exchange Act. Actual results could differ
materially, as the result of such factors as competition in the markets
for the company's products and services and the ability of the Company
to execute its plans. By making these forward-looking statements, the
Company can give no assurances that transactions described in this press
release will be successfully completed, and undertakes no obligation to
update these statements for revisions or changes after the date of this
press release.
